Effect of age on the pharmacokinetics of duloxetine in women
Authors:
- 16 December 2003
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (1) , 54-61
Abstract
Aims The effect of age on duloxetine pharmacokinetics was evaluated in healthy volunteers and in patients with urinary incontinence.Methods Twenty‐four healthy subjects (12 women 65–77 years, and 12 women 32–50 years) were given a single 40‐mg oral dose of duloxetine in Study 1. Plasma concentration‐time data were analysed by noncompartmental pharmacokinetic methods. Sparse plasma samples were obtained from patients with urinary incontinence treated in two phase II studies: 70 women (24–77 years) who received duloxetine 20 mg day−1, 30 mg day−1, or 40 mg day−1 in Study 2A and 128 women (28–64 years) who received duloxetine 20 mg day−1, 40 mg day−1, or 80 mg day−1 in Study 2B. Based upon the combined data, a model was developed to characterize population pharmacokinetics of duloxetine using the nonlinear mixed‐effects modelling program (NONMEM).Results In Study 1, the elderly (≥ 65 years) exhibited a statistically significant slower elimination rate constant λz compared with younger subjects {elderly‐younger difference = −0.022 h−1[95% confidence interval (CI) − 0.036, − 0.008]}. However, no statistically significant differences in either CL/F [elderly‐younger difference = −17.4 l h−1 (95% CI − 41.1, 6.23)] or V/F [elderly‐younger difference = 115.9 l (95% CI − 168.6, 400.4)] were observed. The population pharmacokinetic analysis of Studies 2A and 2B revealed that the CL/F of duloxetine decreased with increasing age. Despite statistical significance, the age effect only accounted for 3% of the interindividual variability in CL/F and unexplained sources of the variation in clearance were still substantial (> 50%). Adverse events were generally mild to moderate, and the incidence of adverse events was generally similar in elderly and non‐elderly participants in these studies.Conclusions Whereas the results suggest that age has an effect on duloxetine pharmacokinetics, primarily reflected as a slower λz in the elderly, the magnitude of mean changes in CL/F, or V/F was small relative to the large interindividual variation in pharmacokinetics. Elderly participants had a safety profile of duloxetine comparable to their younger counterparts. Specific dose recommendations for duloxetine in the elderly are not warranted.Keywords
This publication has 14 references indexed in Scilit:
- METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTSDrug Metabolism and Disposition, 2003
- Pharmacokinetics and Safety of Duloxetine, a Dual‐Serotonin and Norepinephrine Reuptake InhibitorThe Journal of Clinical Pharmacology, 2000
- Pharmacokinetic and Pharmacodynamic Changes in the ElderlyClinical Pharmacokinetics, 1998
- Clinical Pharmacokinetic Considerations in the ElderlyClinical Pharmacokinetics, 1997
- High Performance Liquid Chromatographic Method for the Determination of Duloxetine and Desmethyl Duloxetine in Human PlasmaJournal of Liquid Chromatography & Related Technologies, 1996
- Clinical Pharmacokinetic Considerations in the ElderlyClinical Pharmacokinetics, 1989
- Pharmacodynamic basis for altered drug action in the elderly.1988
- Gastric Emptying Rate in the Elderly: Implications for Drug TherapyJournal of the American Geriatrics Society, 1981
- Pharmacokinetic Consequences of AgingAnnual Review of Pharmacology and Toxicology, 1977
- EFFECT OF AGE ON INTESTINAL ABSORPTION: IMPLICATIONS FOR DRUG ABSORPTION IN THE ELDERLYJournal of the American Geriatrics Society, 1968